Market Newsdesk

Vancouver, B.C., Nov. 24, 2020 (GLOBE NEWSWIRE) — Lomiko Metals Inc. (“Lomiko”) (TSX-V: LMR, OTC: LMRMF, FSE: DH8C) is focused on the exploration and development of flake graphite in Quebec for the new green economy.  Lomiko is pleased to announce the Lomiko Technical, Safety and Sustainability Committee (“LTSSC”) has recommended the acceptance of a Proposal by SGS Canada Inc. to conduct a Metallurgical Process Development Program to the Board of Directors.  This Program has been accepted and approved by the Lomiko Board.

SGS Metallurgical Process Development Plan

Lomiko plans to ship four composites weighing 30 – 35 kg each consisting of high-grade and low-grade samples from the Refractory and the Graphene Battery mineralized zones will be shipped to SGS in Lakefield.  The main scope of the work program includes:

• Sample Preparation
• Chemical Characterisation
• Comminution Testing
• Flowsheet Development
• Environmental Testing 

The samples will be stage-crushed in a series of jaw and cone crushers to minimize the risk of flake degradation and fines generation.  Samples will be extracted for comminution testing, chemical characterization, and the generation of two Master composites. 

Bond ball mill grindability tests will be carried out to establish grinding energy requirements to assist in the design of the preliminary comminution circuit. 

Scoping level flowsheet development testing will be carried out on the two Master composites to establish a conceptual flowsheet.  The primary objectives of the flowsheet development program are to maximize the graphite recovery into a flotation concentrate while minimizing flake degradation. The final concentrates will be subjected to size fraction analyses to determine the flake size distribution and total carbon grade profile of the two mineralized zones. 

The high-grade and low-grade samples of the two mineralized zones will be subjected to variability flotation testing using the flowsheet and conditions that were developed for the two Master composites. Since a flowsheet must be able to treat all domains encountered in a deposit, these variability tests serve the purpose of assessing the robustness of the proposed flowsheet. 

Static geochemical tests will be carried out to assess the acid-generating potential of the La Loutre tailings with and without a sulphide rejection circuit.

Lomiko’s Near Term Goals

 Graphite demand is expected to increase exponentially for the mined natural graphite material, as more is used in the production of spherical graphite for graphite in the anode portion of Electric Vehicle Lithium-ion batteries.

Lomiko completed a $ 750,000 financing October 23, 2020 and plans to work on its near-term goals:

 

1) Complete 100% Acquisition of the Property, currently 80% owned by Lomiko Metals.

2) Complete metallurgy and graphite characterization to confirm li-ion anode grade material.

3) Complete a Technical Report to confirm that the extent of the mineralization equals or surpasses the nearby Imerys Mine, owned by international mining conglomerate.

 A “technical report” means a report prepared and filed in accordance with this Instrument and Form 43-101F1 Technical Report, and includes, in summary form, all material scientific and technical information in respect of the subject property as of the effective date of the technical report;

 4) Complete Preliminary Economic Assessment (PEA)

 A PEA means a study, other than a pre-feasibility or feasibility study, that includes an economic analysis of the potential viability of mineral resources.

 For more information on Lomiko Metals, Promethieus, review the website at www.lomiko.com, and www.promethieus.com, contact A. Paul Gill at 604-729-5312 or email: [email protected].

On Behalf of the Board

 “A. Paul Gill”

 Director, Chief Executive Officer

 We seek safe harbor.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange), accept responsibility for the adequacy or accuracy of this release.

 

Attachment

• graphite demand

A. Paul Gill
Lomiko Metals Inc. (TSX-V: LMR)
6047295312
[email protected]

LAUSANNE, Switzerland, Nov. 24, 2020 (GLOBE NEWSWIRE) — Oculis S.A., a biopharmaceutical company focused on developing transformative topical ophthalmic treatments to improve the sight and lives of patients, announced that Riad Sherif M.D., CEO, will present an overview of the company at the following investor conferences:

• Piper Sandler Healthcare Conference hosted virtually from November 30 to December 3

  Date/Time: The company presentation has been made available on demand as of Monday, November 23 at 10AM ET to registered attendees on the conference website. The presentation will be available for playback throughout the duration of the event. 

  Piper Sandler conferences and events are by invitation only. If you wish to attend, please contact your Piper Sandler representative.www.pipersandler.com

• H.C. Wainwright
  BioConnect
  Healthcare Conference hosted virtually from January 11-14

  Date/Time: The company presentation will be made available online as part of a virtual library the week of the event to registered attendees on the conference website. 

  To access the presentation, please register HERE:https://hcwevents.com/bioconnect/

Dr. Sherif will provide an overview of Oculis’ portfolio and the significant progress it has made during 2020 with the advancement of its lead candidates OCS-01 and OCS-02.

A key focus of the presentations will be on the development of OCS-01 as a potentially transformative and first topical treatment for Diabetic Macular Edema (DME) and as the first once a day steroid for the treatment of inflammation and pain following ocular surgery. Positive clinical results from Phase 2 trials of OCS-01 in both indications were announced this year in February and May, respectively. The Company is now moving to Phase 3 pivotal trials following a positive End of Phase 2 meeting with FDA in both indications. These trials are expected to start in the first half of 2021.

Dr. Sherif will also discuss progress with OCS-02, a novel and a potentially first-in-class topical anti-TNF alpha antibody. OCS-02 has successfully completed two proof-of-concept (POC) clinical trials in Dry Eye Disease (DED) and Acute Anterior Uveitis and aims to initiate Phase 2b trials in 2021. In DED, Oculis will continue to validate a novel biomarker identified in patients who showed a highly positive response to treatment. If confirmed in the next trial, this finding could accelerate and de-risk the pivotal trials program and potentially lead to a novel, personalized medicine approach to the treatment of DED, with an associated companion diagnostic.

About Oculis

Oculis S.A. is a biopharmaceutical company focused on developing transformative topical ophthalmic treatments using its innovative formulation technologies to improve the sight and lives of patients. Oculis’ novel topical (eye drop) treatments are non-invasive and represent an unprecedented technical advance for patients with retinal and front-of-the-eye diseases.

The Company’s leading clinical candidates include OCS-01 and OCS-02:

• OCS-01 is a novel, high concentration, preservative free, topical formulation of dexamethasone based on Oculis’ proprietary Solubilizing Nanoparticle (SNP) technology. OCS-01 is moving to Phase 3 in two indications – Diabetic Macular Edema (DME) and post-ocular surgery – following a positive End-of-Phase 2 meeting with FDA. OCS-01 is poised to provide the first non-invasive topical treatment option for DME patients, and the first once a day, preservative free steroid for inflammation and pain following ocular surgery.
• OCS-02 is a novel topical anti-TNF alpha antibody. It has successfully completed two proof-of-concept clinical trials in Dry Eye Disease (DED) and Acute Anterior Uveitis and is progressing into Phase 2b. In DES, Oculis is continuing its investigation of a novel biomarker method identified in the POC study. Oculis is a leading innovator to drive the first, non-invasive, predictive and personalized medicine in DED. In Uveitis, the goal is to evaluate OCS-02 as a steroid-sparing maintenance treatment for Chronic Anterior Uveitis.

In addition, Oculis’ formulation discovery focus and capabilities are enabling the development of a pipeline of topical drugs targeting sight-threatening eye diseases that affect both the anterior and posterior segments of the eye.

Oculis has an experienced management team from global ophthalmic companies and is supported by leading international life science investors. Oculis is headquartered in Lausanne, Switzerland, with research operations in Iceland, and U.S. operations in Boston, MA.

To learn more, visit www.oculis.com

Contacts

Oculis
Dr. Riad Sherif, CEO
[email protected]
Sylvia Cheung, CFO
[email protected]
Louie-Anne Gauthier, VP, Strategic Marketing and BD&L
[email protected]

Media Relations

Citigate Dewe Rogerson
Mark Swallow / Sylvie Berrebi / Marine Perrier
[email protected]
+44 (0)20 7638 9571

WASHINGTON, DC, Nov. 24, 2020 (GLOBE NEWSWIRE) — via NewMediaWire — Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing technology and financial services solutions, is pleased to announce the highlights from the third quarter released disclosures and updates about the company’s plans for the remainder of the fourth quarter of 2020. Xalles has achieved many results during the last quarter and is looking ahead to a strong finish to 2020.

Q3 Results

Xalles Holdings released its Quarterly Report and Financial Statements on November 22, 2020 for the quarter ending September 30, 2020. Xalles recorded its fourth consecutive quarter of profitability. Xalles also achieved its single largest quarter for revenue and income.

Xalles Holdings consolidated revenue was $354,648 with income of $182,181 for the third quarter ending September 30, 2020.

During the third quarter, Xalles initiated the process to complete the financial audits which will allow the company to become fully SEC reporting in the fourth quarter. This process was initiated after the company’s management team decided to withdrawal a Tier I Reg A+ application with the aim to have a Tier II Reg A+ application to be submitted as soon as the company becomes fully SEC reporting again.

Q4 Interim Results and Plans

Argus Technology Partners has added a Data Asset Management practice to its services offerings. This set of service offerings includes network and data inventorying, analytics and governance. The new products and services enhance their existing offerings of Biometric Security, Quantum Computing and Software Integration.

Xalles is expecting to close the two previously announced acquisitions before the end of this year, specifically, Adaptive Metadata Solutions and 1Rivet Global. Both companies will be key to realizing significantly larger revenue gains in 2021.

Xalles is planning to acquire or license additional payment technology during the fourth quarter to modernize the Co-Owners Rewards and Global Savings Network projects and accelerate their growth in 2021.

In this quarter Xalles will invite the first group of small fintech firm applicants to become part of the Xalles Fintech Studio.  This is a growth program which will provide unique opportunities to a select group of applicants that allows their companies to succeed while under Xalles’ guidance.

The Xalles Holdings strategy also includes a plan to uplist to the OTCQB (Quotation Board) prior to the end of 2020.

About Xalles Holdings Inc. (OTC: XALL)

Xalles Holdings Inc. is a holding company that focuses on direct investments in disruptive fintech companies. The company actively seeks acquisition targets in which it can invest and accelerate growth, targeting companies with solid management teams and business models, large total attainable markets (TAM), and lucrative exit opportunities. The company places emphasis on leveraging blockchain technologies to provide industry-leading financial reconciliation and auditing solutions, which, over time, will allow for the capture of recurring revenue streams. For more information visit: http://Xalles.com

Forward-Looking Statements Disclaimer:

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. In some cases, you can identify forward-looking statements by the following words: “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “ongoing,” “plan,” “potential,” “predict,” “project,” “should,” “will,” “would,” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements are not a guarantee of future performance or results, and will not necessarily be accurate indications of the times at, or by, which such performance or results will be achieved. Forward-looking statements are based on information available at the time the statements are made and involve known and unknown risks, uncertainty and other factors that may cause our results, levels of activity, performance or achievements to be materially different from the information expressed or implied by the forward-looking statements in this press release. This press release should be considered in light of all filings of the Company that are contained in the Edgar Archives of the Securities and Exchange Commission at www.sec.gov and in OTC Markets at www.otcmarkets.com

Investor Relations Contact:

[email protected]

www.Xalles.com

202.595.1299 Office

BOISE, Idaho, Nov. 24, 2020 (GLOBE NEWSWIRE) — Albertsons Companies announced today that it has taken another step in enhancing its safe environment by implementing a contactless temperature check and health screening solution for associates and vendors. The new technology, now being deployed across all Albertsons Companies locations, enables a safer and more reliable health screening process for those who work in their stores and facilities. 

After extensive testing and process refinements, the selected technology, provided by Turing Video Inc., leverages a built-in touchless body temperature scanner and a digital COVID-19 health questionnaire. The new screening solution can help to avoid potential exposure for health screeners while ensuring effective temperature screening for all associates.  The enhanced process will be implemented across all markets regardless of their COVID-19 risk state, enabling Albertsons Companies to adhere to the latest CDC recommendations and regional mandates pertaining to health screenings. Upon successful completion of the temperature screening and validation of the heath questionnaire, visible stickers are printed with “CLEAR” and the associate’s photo, which can then be worn by those screened who are not in food production areas. For those in food production positions, the stickers will be logged in the department.

“The health and safety of associates working in our facilities is a top priority, and the enhanced health screening process provides us with peace of mind while promoting a healthy workplace” said Susan Morris, Chief Operations Officer, Albertsons Companies. “After testing multiple options, we are grateful for the support and partnership of Turing Video to deliver an effective, scalable solution.” 

“Turing Video is excited to team up with Albertsons in this partnership,” said Jerry Zhong, Co-Founder and President of Turing Video. “A quick, easy, contactless, and effective health screen is a key to containing the spread of COVID-19, and Albertsons Companies quickly recognized the value in implementing this system.”

About Albertsons Companies

Albertsons Companies is a leading food and drug retailer in the United States. The company operates stores across 34 states and the District of Columbia under 20 well-known banners including Albertsons, Safeway, Vons, Jewel-Osco, Shaw’s, Acme, Tom Thumb, Randalls, United Supermarkets, Pavilions, Star Market, Haggen and Carrs. The company is committed to helping people across the country live better lives by making a meaningful difference, neighborhood by neighborhood. In 2019 alone, along with the Albertsons Companies Foundation, the Company gave $225 million in food and financial support. In 2020, the Company made a $53 million commitment to community hunger relief efforts and a $5 million commitment to organizations supporting social justice. These efforts have helped millions of people in the areas of hunger relief, education, cancer research and treatment, social justice and programs for people with disabilities and veterans’ outreach.

Christine Wilcox
Albertsons Companies
[email protected]

HOUSTON, Nov. 24, 2020 (GLOBE NEWSWIRE) — via InvestorWire – CNS Pharmaceuticals, Inc. (NASDAQ: CNSP), a biopharmaceutical company specializing in the development of novel treatments for primary and metastatic cancers of the brain and central nervous system, today announces that it has been featured in a broadcast via NetworkNewsAudio (NNA), a solution that delivers additional visibility, recognition and brand awareness in the investment community via distribution to thousands of syndication points. The audio press release covers CNS Pharmaceuticals’ recent submission of an Investigational New Drug (“IND”) application to the U.S. Food & Drug Administration (“FDA”) for its brain cancer drug, Berubicin, as well as the Company’s plans to commence Phase 2 trials during the first quarter of 2021.

To hear the audio production, visit: https://www.nnw.fm/O2OcK

To read the original press release, visit: https://nnw.fm/1Qib1

“Our laser focus from the beginning has been to start the next phase of the investigation of Berubicin for the treatment of this deadly disease as quickly as possible,” stated John Climaco, CEO of CNS Pharmaceuticals. “Our team has worked tirelessly for the past year, making several inroads on our manufacturing and clinical efforts to achieve this important milestone. We believe we are optimally positioned to continue to execute our plan and initiate our Phase 2 trial in the first quarter of 2021. We continue to build on the positive results Berubicin demonstrated in the Phase 1 study in high grade gliomas and look forward to advancing its clinical development in these patients, with the end goal of addressing the unmet medical need of better treatment for patients diagnosed with GBM.”

The planned Phase 2 trial will evaluate the efficacy of Berubicin in patients with GBM who have failed primary treatment for their disease, and results will be compared to the current standard of care, with 2 to 1 randomization of the 243 patients to Berubicin or Lomustine. The trial will include an interim analysis that will evaluate the comparative effectiveness of these treatments. The trial’s adaptive design is intended to allow this interim analysis of the data to demonstrate meaningful differences in efficacy between treatments and then to allow an adjustment to the size of the patient population in the trial for maximum efficiency in terms of time in development. Based on this, the trial has the potential to provide data to the FDA that may allow an expedited pathway for development. However, there can be no assurance that the FDA will support any potential request for an expedited pathway to approval or further development.

Earlier this month, CNS Pharmaceuticals hosted a virtual presentation to discuss the clinical trial design for its upcoming Phase 2 U.S. trial for Berubicin. To view the recorded webinar, visit https://cnspharma.com/webcast-november-2020/.

About CNS Pharmaceuticals, Inc.

CNS Pharmaceuticals is developing novel treatments for primary and metastatic cancers of the brain and central nervous system. Its lead drug candidate, Berubicin, is proposed for the treatment of glioblastoma multiforme (GBM), an aggressive and incurable form of brain cancer. CNS holds a worldwide exclusive license to the Berubicin chemical compound and has acquired all data and know-how from Reata Pharmaceuticals, Inc. related to a completed Phase 1 clinical trial with Berubicin in malignant brain tumors, which Reata conducted in 2006. In this trial the overall response rate of stable disease or better was 44%. This 44% disease control rate was based on 11 patients (out of 25 evaluable patients) with stable disease, plus responders. One patient experienced a durable complete response and remains cancer-free as of Feb. 20, 2020. These Phase 1 results represent a limited patient sample size and, while promising, are not a guarantee that similar results will be achieved in subsequent trials. By the end of 2020, CNS expects to commence a Phase 2 clinical trial of Berubicin for the treatment of GBM in the U.S., while a sub-licensee partner undertakes a Phase 2 trial in adults and a first-ever Phase 1 trial in pediatric GBM patients in Poland. Its second drug candidate, WP1244, is a novel DNA binding agent that has shown in preclinical studies that it is 500 times more potent than the chemotherapeutic agent daunorubicin in inhibiting tumor cell proliferation.

For more information, visit: www.cnspharma.com

About NetworkNewsAudio

NetworkNewsAudio (“NNA”), one of 50+ brands within the InvestorBrandNetwork (“IBN”), allows you to sit back and listen to market updates, CEO interviews and AudioPressRelease (“APR”) productions. These audio clips provide snapshots of position, opportunity and momentum. NNA can assist by cutting through the overload of information in today’s market, while bringing its clients unparalleled visibility, recognition and brand awareness. IBN is where news, content and information converge. IBN is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, IBN has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of 5,000+ key syndication outlets across the nation.

For more information, visit: www.NetworkNewsAudio.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://IBN.fm/Disclaimer

Forward-Looking Statements

Some of the statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act of 1995, which involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, the ability of the Company to seek accelerated approval from the FDA of a New Drug Application (NDA) following the planned Berubicin trial. These statements relate to future events, future expectations, plans and prospects. Although CNS believes the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward-looking statements. CNS has attempted to identify forward-looking statements by terminology including ”believes,” ”estimates,” ”anticipates,” ”expects,” ”plans,” ”projects,” ”intends,” ”potential,” ”may,” ”could,” ”might,” ”will,” ”should,” ”approximately” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including those discussed under Item 1A. “Risk Factors” in CNS’s most recently filed Form 10-K filed with the Securities and Exchange Commission (“SEC”) and updated from time to time in its Form 10-Q filings and in its other public filings with the SEC. Any forward-looking statements contained in this press release speak only as of its date. CNS undertakes no obligation to update any forward-looking statements contained in this press release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.

Corporate Communications:

InvestorBrandNetwork (IBN)
Los Angeles, California
www.InvestorBrandNetwork.com
310.299.1717 Office
[email protected]

VANCOUVER, British Columbia, Nov. 24, 2020 (GLOBE NEWSWIRE) — Aben Resources Ltd. (TSX-V: 

ABN

) (OTCQB: ABNAF) (Frankfurt: E2L2) (“Aben” or “the Company”) announces that the Company’s Board of Directors has approved the amendment of certain common share purchase warrants (the “Warrants”), that were issued by way of private placement, by extending the expiry date one additional year.

The Warrants affected are 8,560,000 share purchase warrants issued on June 29, 2017 with an expiry date of December 29, 2020 and exercisable at $0.15 per common share. The new expiry date will be December 29, 2021 and the exercise price shall remain the same. The Company will not be sending out new warrant certificates unless requested by the holder. The warrant amendment remains subject to the approval of the TSX Venture Exchange.

Aben also announced the appointment of Simon Dyakowski as a director of the company. Mr. Dyakowski is currently CEO of Aztec Minerals Corp. and GSP Resource Corp., both TSXV-listed mineral exploration companies.

About Aben Resources:

Aben Resources is a Canadian gold exploration company developing gold-focused projects in British Columbia and the Yukon Territory. Aben is a well-funded junior exploration company.

Forrest Kerr Gold Project, Golden Triangle, BC
claims
m
ap:

https://abenresources.com/site/assets/files/4087/abn_forrest_kerr_project_map.pdf

For further information on Aben Resources Ltd. (TSX-V: ABN), visit our Company’s web site at www.abenresources.com.

ABEN RESOURCES LTD.

“Jim Pettit”

______________________
JAMES G. PETTIT
President & CEO

<sup>For further information contact:

Aben Resources Ltd.

Telephone: 604-687-3376

Toll Free: 800-567-8181

Facsimile: 604-687-3119

Email: info@abenresources.com</sup>

^{Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.}

^{This release includes certain statements that may be deemed to be “forward-looking statements”. All statements in this release, other than statements of historical facts, that address events or developments that management of the Company expects, are forward-looking statements. Although management believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance, and actual results or developments may differ materially from those in the forward-looking statements. The Company undertakes no obligation to update these forward-looking statements if management’s beliefs, estimates or opinions, or other factors, should change. Factors that could cause actual results to differ materially from those in forward-looking statements, include market prices, exploration and development successes, continued availability of capital and financing, and general economic, market or business conditions. Please see the public filings of the Company at www.sedar.com for further information.}

SAN ANTONIO, Nov. 24, 2020 (GLOBE NEWSWIRE) — Ecoark Holdings, Inc. (“Ecoark”) (OTC: ZEST), today announced that the Company will be participating in the Capital One Securities 15th Annual Energy Conference, to be held virtually on December 7-9, 2020. The Company will be participating in virtual one-on-one meetings.

About Ecoark Holdings, Inc
.

Founded in 2011, Ecoark is a diversified holding company. The company has three wholly owned subsidiaries: Zest Labs, Inc. (“Zest Labs”), Banner Midstream Corp (“Banner Midstream”) and Trend Discovery Holdings (“Trend Discovery”). Zest Labs, offers the Zest Fresh^TM solution, a breakthrough approach to quality management of fresh food, is specifically designed to help substantially reduce the amount of food loss the U.S. experiences each year. Banner Midstream is engaged in oil and gas exploration, production, and drilling operations on over 20,000 cumulative acres of active mineral leases in Texas, Louisiana, and Mississippi. Banner Midstream also provides transportation and logistics services and procures and finances equipment to oilfield transportation services contractors. Trend Discovery invests in a select number of early stage startups each year as part of the fund’s Venture Capital strategy; we are open-minded investors with a founder-first mentality. Trend Discovery LP has an audited track record of uncorrelated outperformance of the S&P 500 since inception.

Investor Relations:

John Mills
ICR
646-277-1254
[email protected]

New York City, Nov. 24, 2020 (GLOBE NEWSWIRE) — The global upsurge in COVID-19 has kept testing and Co-Diagnostics (NASDAQ: CODX) under the analysts’ microscope. 

Within its client circular, the analyst from H.C. Wainwright & Co. predicted that Co-Diagnostics’ Logix Smart ABC (Influenza A/Influenza B/COVID-19) and Logix Smart SARS-CoV-2 (genes RdRp/E) multiplex tests, which it considers both highly accurate and affordable, could drive future domestic and international sales. This followed the company announcing they had obtained CE markings for both tests, after already having begun distributing the ABC test on a Research Use Only (RUO) basis to U.S. CLIA laboratories in the first week of October 2020.

The importance of achieving a CE marking for the new test cannot be overemphasised since it allows this new test to be freely marketed and sold in all European Member states, as well as any other region that accepts a CE marking as valid regulatory approval. 

“We believe the company may seek Emergency Use Authorization (EUA) and ultimately 510(K) clearance for the ABC multiplex panel. This panel could drive both near-term and long-term sales, in our view, as patients presenting flu-like symptoms are likely to be required to test for COVID-19 even after the COVID-19 spread has largely resolved,” Wainwright analyst Yi Chenwrote.

He adds: “We expect the company to continue to report top-line revenue similar to levels seen in 2Q20 and 3Q20. Our revenue projections for 4Q20 and the next 12 months (4Q20 to 3Q21) are $22M and $90M, respectively. The company’s operations could be sustainably profitable, in our view, particularly given the recent resurgence of the COVID-19 pandemic.“

Further mentions of note were the company’s saliva-based CRL Rapid Response COVID-19 test, which is already being sold through its partnership with Clinical Reference Lab.   With this technology being further perfected, the implication is that it could propel top-line growth over the next few quarters.

Wainwright currently have a Buy rating on the company with a price target of $29 per share.

The Maxim Group  also maintained a Buy rating albeit with a price target of $20 per share.  While recognising that the Q3 results were lower than some had hoped, analyst Jason McCarthy strongly believes that the company may surprise the street with a lot more upside. 

“…see it from our perspective and there are a lot of positives in this story and what CDI has accomplished in 2020 has been impressive. In less than a year, the company has advanced essentially years, in our view.

“COVID pandemic has whipsawed the markets, especially those companies right in the thick of it, like CDI. That said, the miss on revenue should not detract from the big picture for CDI. COVID testing with PCR is here to stay and what CDI should have, even without any further growth, is a baseline of $70M-$100M in revenue per year and a base to grow its agro, oncology, and infectious diseases tests (oral saliva one-step COVID, ABC for flu, and COVID combined, TB, HepB, vector borne diseases and more),” the analyst said.

Mr. McCarthy continued, “Let’s also first clear up something that may be confusing to the street. Important to understand is that the company is not a CLIA lab actually performing PCR tests for COVID. CDI sells the actual PCR test kit with CoPrimers to the CLIA labs…This difference between CDI and CLIA labs or large testing providers like a LabCorp or Qiagen must be clear. As such, $20M-$25M in 2Q and 3Q is quite a large amount of tests sold by CDI. Recall, this company was just in the early stages of commercialization with its ID-focused tests in India with CoSara, early stage in Agro with LGC, and so on; <$1M in revenue a year. This was pre-COVID, in just 6 months that number is over $40M for COVID alone, and it is profitable.”

Disclosure: Co-Diagnostics Inc is a client of BDA International.

About BDA International, Inc.:

BDA International is an independent global Investor Relations firm offering a wide range of IR-related analysis, research and advisory services. In particular, we provide and are compensated for service packages that include strategic action plans and investor/market perception studies to help entities improve communication with customers and investors, and to increase their visibility. BDA International has received no direct compensation related to this release but its principles hold shares of client companies in our personal portfolios, including CODX. BDA International accepts sole responsibility for the content and distribution of the foregoing release, which does not contain any previously unpublished or non-public information. Parties interested in learning more about the relationship between BDA and CODX may do so via the contact information at the bottom of this release.

Disclaimer

The information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained in this analysis reflect our current judgment and are subject to change without notice. We do not accept any responsibility or liability for any losses, damages or costs arising from an investor’s or other person’s reliance on or use of this analysis. This analysis is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities, nor a recommendation of any security, although members of the BDA may at times hold a position in the company covered within the article. Co-Diagnostics is a client of BDA International. Past gains are not a representative of future gains. The opinions herein contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. When used herein, the words “anticipate,” “intend,” “estimate,” “believe,” “expect,” “plans,” “should,” “potential,” “forecast,” and variations of such words and similar expressions are intended to identify forward-looking statements. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. A company’s actual results could differ materially from those described in any forward-looking statements contained herein. BDA is not a licensed broker, broker dealer, market maker, investment advisor, analyst or underwriter. We recommend that you use the information found herein as an initial starting point for conducting your own research in order to determine your own personal opinion of the companies discussed herein before deciding whether or not to invest. You should seek such investment, tax, financial, accounting or legal advice appropriate for your particular circumstances. Information about many publicly traded companies and other investor resources can be found at www.sec.gov. Investing in securities is speculative and carries risk.

Investor Relations Contact:
Mushtaq Dost                                                                      
BDA International    
www.bda-ir.com

[email protected]

Webinar
, sponsored by
Utimaco
,
with experts
from Microsoft Research, NIST, University of Waterloo

PRINCETON JUNCTION, N.J., Nov. 24, 2020 (GLOBE NEWSWIRE) — As quantum computing evolves at an increased pace, research in the corporate, public and academic sectors are building the foundation for essential cybersecurity practices. The Secure Technology Alliance announced today a virtual education session, sponsored by Utimaco, that will explore this emerging risk and outline best practices for a quantum-resistant IT infrastructure. Leading experts on post-quantum cryptography will share their expertise and provide concrete recommendations on how to best assess your risk and prepare ahead of the post quantum era.

The education session, “Applied Crypto Symposium – Cybersecurity in the Age of Quantum Computing,” will be held December 9, 2020 from 12pm ET/9am PT to 2:15pm ET/11:15am PT. Registration is available at https://www.securetechalliance.org/applied-crypto-symposium/.

Speakers are: Dieter Bong, Utimaco; Lily Chen, NIST; Brian LaMacchia, Microsoft Research; Michele Mosca, University of Waterloo; and Randy Vanderhoof, Secure Technology Alliance.

“Maintaining the integrity of critical infrastructures is a top priority, and this means adapting to new threats, smart hackers and even smarter technology,” said Randy Vanderhoof, executive director of the Secure Technology Alliance. “The future iterations of quantum computers will possess the processing power to crack the asymmetric algorithms that serve as the foundation of cryptography. Understanding how to prepare is top-of-mind for many cybersecurity experts, and this education session will provide necessary insight into implementing quantum-resistant IT infrastructures with an emphasis on federal and defense systems.”

This session is for cybersecurity professionals interested in encryption, cryptography, data protection, key distribution and management, and responsibilities related to the protection of critical infrastructure in federal government and public sector, aerospace, defense, financial services, payments, IoT networks, automotive and telecommunications.

Experts will discuss:

• The threat posed by quantum computers to the digital economy, including the timeline and key milestones
• Advancements in corporate and academic research to counter the threat of quantum computing
• Best practices to protect critical infrastructure ahead of the post-quantum era

TWEET THIS: #PostQuantumCrypto – learn from NIST, Microsoft Research & Utimaco on how to secure your infrastructure at the @SecureTechOrg webinar on cybersecurity in the age of quantum computing, Dec. 9 at 12pmET/9amPT https://www.securetechalliance.org/applied-crypto-symposium/

About the Secure Technology Alliance

The Secure Technology Alliance is the digital security industry’s premier association. The Alliance brings together leading providers and adopters of end-to-end security solutions designed to protect privacy and digital assets in payments, mobile, identity and access, healthcare, transportation and the emerging Internet of Things (IoT) markets.

The Alliance’s mission is to stimulate understanding, adoption and widespread application of connected digital solutions based on secure chip and other technologies and systems needed to protect data, enable secure authentication and facilitate commerce.

The Alliance is driven by its U.S.-focused member companies. They collaborate by sharing expertise and industry best practices through industry and technology councils, focused events, educational resources, industry outreach, advocacy, training and certification programs. Through participation in the breadth of Alliance activities, members strengthen personal and organizational networks and take away the insights to build the business strategies needed to commercialize secure products and services in this dynamic environment.

For more information, please visit www.securetechalliance.org.

About
Utimaco

Utimaco is one of the world’s leading provider of cybersecurity solutions, with headquarters in Aachen (Germany) and Campbell, CA (USA). Utimaco specializes in encryption, key management and data protection solutions delivered on premise and as a service.

Specifically, we design, develop, manufacture, operate and support hardware security modules and key management solutions, as well as compliance solutions for telecommunication providers in the field of regulation.
Utimaco stands for recognized product quality, user-friendly software, excellent support and products and solutions that effectively meet market requirements.

For more information, please visit http://www.utimaco.com

CONTACT:

Adrian Loth and Dana Kringel
Montner Tech PR
203-226-9290
aloth@montner.com
[email protected]

FREMONT, Calif., Nov. 24, 2020 (GLOBE NEWSWIRE) — Identiv, Inc. (NASDAQ: INVE), a global leader in digital security and identification, will be presenting at Imperial Capital’s 17th Annual Virtual Security Investor Conference, which is being held December 2-3, 2020.

Identiv’s Chief Executive Officer Steven Humphreys and Chief Financial Officer Sandra Wallach are scheduled to present on Wednesday, December 2 at 12:30 PM ET. Management will also hold one-on-one virtual meetings with institutional investors and analysts throughout the day.

To receive additional information or to schedule a one-on-one meeting, please contact Identiv’s IR team at [email protected].

About
Identiv

Identiv, Inc. is a global leader in digitally securing the physical world. Identiv’s platform encompasses RFID and NFC, cybersecurity, and the full spectrum of physical access, video, and audio security. Identiv is a publicly traded company, and its common stock is listed on the NASDAQ Stock Market LLC in the U.S. under the symbol “INVE.” For more information, visit identiv.com.

Investor Relations Contact:

Matt Glover and Charlie Schumacher
Gateway Investor Relations
+1 949.574.3860
[email protected]

Media Contact:

[email protected]